论文部分内容阅读
P-糖蛋白(P-gp)是一种经典多药耐药相关蛋白,是评价化疗药物是否耐药的重要因素。化疗药物的应用越来越多,使肿瘤患者症状得到缓解,同时手术成功率提高,死亡率下降等都推动着化疗相关研究的发展,但随之出现的问题是肿瘤多药耐药现象(MDR),这成为化疗失败的关键原因。作为第一个被发现与MDR有关的膜蛋白P-gp,人们围绕其展开大量的研究,试图从中找出解决MDR的有效方法。本文就如何优化P-gp给药模式,从P-gp抑制剂的机制、提高药物生物利用度和运转率、抗微生物疗法、肿瘤化疗的研究进展等方面作一综述。
P-glycoprotein (P-gp) is a classic multidrug resistance-related protein that is an important factor in evaluating the resistance of chemotherapeutic drugs. More and more chemotherapy drugs are used to alleviate the symptoms of cancer patients, meanwhile, the success rate of surgery and the mortality rate are decreasing, which all promote the development of chemotherapy-related research. However, the multi-drug resistance phenomenon (MDR ), Which is the key reason for the failure of chemotherapy. As the first membrane protein P-gp to be found in MDR, a great deal of research has been carried out around it to try to find an effective method to solve MDR. This article reviews how to optimize the mode of P-gp administration, from the mechanism of P-gp inhibitor, to improve the bioavailability and turnover rate of drugs, anti-microbial therapy and the progress of tumor chemotherapy.